Jul 12, 2022 / 07:30AM GMT
Operator
Good morning, and welcome to the Q2 2022 earnings call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to Gunilla Osswald, CEO. Please go ahead.
Gunilla Osswald - BioArctic AB(publ)-CEO
Thank you. Good morning, and welcome to BioArctic's presentation from the second quarter. I'm Gunilla Osswald, and I'm the CEO of BioArctic, and I will share today's presentation with our CFO, Jan Mattsson. I will give an update on lecanemab and some recent highlights. Lecanemab is progressing really well, and the marketing application for an accelerated approval has been accepted by the FDA, and they have granted a priority review.
I think it looks very promising for lecanemab, and it's a very exciting time for us with the Phase III readout of the Clarity AD study coming closer. And we also have a potential for an accelerated approval in the U.S. within 6 months. I will, of course, talk more about that here today.
Next slide, please. BioArctic is listed at Nasdaq
Q2 2022 BioArctic AB Earnings Call Transcript
Jul 12, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers